Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia

Bibliographische Detailangaben
Hauptverfasser:	Craddock, C, Versluis, J, Labopin, M, Socie, G, Huynh, A, Deconinck, E, Volin, L, Milpied, N, Bourhis, JH, Rambaldi, A, Chevallier, P, Blaise, D, Manz, M, Vellenga, E, Vekemans, MC, Maertens, J, Passweg, J, Vyas, P, Schmid, C, Löwenberg, B, Ossenkoppele, G, Mohty, M, Cornelissen, JJ, Nagler, A, Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON‐SAKK
Format:	Journal article
Sprache:	English
Veröffentlicht:	John Wiley and Sons, Ltd. 2017

Ähnliche Einträge

Characterization of factors determining the kinetics of disease relapse after allogeneic Stem Cell Transplantation (allo-SCT) or chemotherapeutic consolidation for Acute Myeloid Leukaemia (AML) in First CR: A survey from HOVON-SAKK and the acute leukaemia working party of the EBMT
von: Craddock, C, et al.
Veröffentlicht: (2016)

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1
von: Jurjen Versluis, et al.
Veröffentlicht: (2017-02-01)

A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia
von: Simona Piemontese, et al.
Veröffentlicht: (2017-01-01)

Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT
von: Simona Piemontese, et al.
Veröffentlicht: (2019-07-01)

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia
von: Eolia Brissot, et al.
Veröffentlicht: (2015-03-01)

Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
von: Xavier Poiré, et al.
Veröffentlicht: (2018-02-01)

Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT
von: Francesco Saraceni, et al.
Veröffentlicht: (2023-10-01)

Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation
von: Patrice Chevallier, et al.
Veröffentlicht: (2011-09-01)

Chemotherapeutic trial for acute leukemia in Iraq
von: Chemotherapeutic trial for acute leukemia in Iraq
Veröffentlicht: (2009-12-01)

Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status
von: Ali Bazarbachi, et al.
Veröffentlicht: (2016-01-01)

Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT
von: Angelique V.M. Brands-Nijenhuis, et al.
Veröffentlicht: (2016-02-01)

Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database
von: Yuqian Sun, et al.
Veröffentlicht: (2016-08-01)

The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed
von: Katerina Bakunina, et al.
Veröffentlicht: (2022-02-01)

Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial
von: Niek G. van der Maas, et al.
Veröffentlicht: (2024-03-01)

Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation
von: Mohamad Mohty, et al.
Veröffentlicht: (2008-02-01)

Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party
von: Andrea Bacigalupo, et al.
Veröffentlicht: (2010-06-01)

Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
von: Dalila Salvatore, et al.
Veröffentlicht: (2018-08-01)

Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
von: Sebastian Giebel, et al.
Veröffentlicht: (2017-01-01)

Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
von: Kazimierz Halaburda, et al.
Veröffentlicht: (2020-06-01)

S238: MATCHED RELATED VERSUS UNRELATED VERSUS HAPLOIDENTICAL DONORS FOR ALLOGENEIC TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST COMPLETE REMISSION AFTER TWO INDUCTION COURSES: A STUDY FROM THE ALWP/EBMT
von: A. Nagler, et al.
Veröffentlicht: (2022-06-01)

Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
von: Jesse M. Tettero, et al.
Veröffentlicht: (2023-04-01)

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
von: Charles Craddock, et al.
Veröffentlicht: (2016-07-01)

Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT
von: Xavier Poiré, et al.
Veröffentlicht: (2020-02-01)

Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
von: Xavier Poiré, et al.
Veröffentlicht: (2017-01-01)

Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis
von: Andrea Bacigalupo, et al.
Veröffentlicht: (2015-05-01)

Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia
von: Mohamad Mohty, et al.
Veröffentlicht: (2017-01-01)

Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI
von: Arnon Nagler, et al.
Veröffentlicht: (2019-07-01)

P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
von: Jesse Tettero, et al.
Veröffentlicht: (2023-08-01)

Cellular-Based Therapies in Systemic Sclerosis: From Hematopoietic Stem Cell Transplant to Innovative Approaches
von: Elisabetta Xue, et al.
Veröffentlicht: (2022-10-01)

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT
von: Jiří Pavlů, et al.
Veröffentlicht: (2019-10-01)

Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG
von: Roland B. Walter, et al.
Veröffentlicht: (2015-10-01)

Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
von: Jesse M. Tettero, et al.
Veröffentlicht: (2022-10-01)

Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France
von: Myriam Labopin, et al.
Veröffentlicht: (2014-03-01)

Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial
von: Patrice Chevallier, et al.
Veröffentlicht: (2014-09-01)

Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study
von: Ali Bazarbachi, et al.
Veröffentlicht: (2019-03-01)

Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party
von: Ali Bazarbachi, et al.
Veröffentlicht: (2019-09-01)

Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia
von: Francesco Lo-Coco, et al.
Veröffentlicht: (2008-07-01)

Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy
von: Tereza Coman, et al.
Veröffentlicht: (2013-05-01)

Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?
von: Tara M. Robinson, et al.
Veröffentlicht: (2018-06-01)

Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML
von: Christian M. Vonk, et al.
Veröffentlicht: (2025-03-01)